Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer
10.12259/j.issn.2095-610X.S20250510
- VernacularTitle:阿美替尼对比奥希替尼治疗EGFR突变晚期NSCLC的临床疗效研究
- Author:
Shengxi YANG
1
;
Jiade ZHU
;
Qiurui LI
;
Wenlian TU
Author Information
1. 云南省第一人民医院药学部/昆明理工大学附属昆华医院药学部,云南 昆明 650032;大理大学药学院,云南 大理 671000
- Keywords:
Osimertinib;
Aumolertinib;
Clinical efficacy;
Adverse drug reactions;
Non-small cell lung cancer
- From:
Journal of Kunming Medical University
2025;46(5):89-95
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of osimertinib and aumolertinib in the treatment of advanced non-small cell lung carcinoma(NSCLC)with epidermal growth factor receptor(EGFR)mutation.Methods A total of 139 patients with EGFR-mutated advanced NSCLC treated in the First People's Hospital of Yunnan Province from January,2019 to December,2022 were retrospectively collected.After screening by that row of criteria,104 patients were included in this study.According to the treatment drugs,they were divided into osimertinib group and aumolertinib group,with 52 cases in each group.The osimertinib group received osimertinib mesylate tablets 80 mg once daily,and the aumolertinib group received aumolertinib mesylate tablets 110 mg once daily.The disease control rate(DCR),objective remission rate(ORR)and progression-free survival(PFS)of the two groups were observed.PFS and overall survival(OS)were evaluated.The Cox regression model was used to analyze the key factors affecting patient survival.Results The ORR of aumolertinib group was significantly higher than that of osimertinib group.The median progression-free survival(mPFS)of aumolertinib group was significantly longer than that of osimertinib group(P=0.045).Cox regression model showed that clinical stage Ⅲ(HR=2.25,95%Cl 1.28～3.95,P=0.005),no brain metastasis(HR=0.59,95%Cl 0.35～0.98,P=0.040),third generation TKI type aumolertinib(HR=1.82,95%CI 1.15～2.87,P=0.011).Conclusion Aumolertinib and osimertinib have similar clinical efficacy in the treatment of advanced NSCLC patients with EGFR mutation.However,in terms of long-term efficacy,aumolertinib has significantly better median PFS and overall OS,and higher safety than osimertinib.
